GERMANTOWN, Md. – Medical technology company Senseonics will work with TypeZero Technologies to develop an artificial pancreas and a decision support system that uses Senseonics’ Eversense CGM System for diabetes management.
The goal of the collaboration is to integrate glucose readings from the Eversense system into TypeZero’s inControl software platform, which includes decision support and artificial pancreas system solutions.
“The continuous long-term use of an accurate sensor, such as Eversense, combined with the clinically proven treatment algorithms of inControl has the promise of impacting both pump and pen users in a positive and meaningful way,” said Tim Goodnow, president and CEO of Senseonics, in a statement.
Eversense is a long-term, implantable continuous glucose monitoring system for people with diabetes. Combined with insulin data, the continuous glucose readings from the Eversense sensor will equip TypeZero’s artificial pancreas algorithms to automatically adjust and regulate insulin delivery via a user’s insulin pump.
The integration will also enable TypeZero’s decision support system to recommend optimal basal and bolus doses for insulin pen users.
“In many ways, CGM is the heartbeat of our artificial pancreas and decision support technologies, and integrating our inControl platform with the reliable and durable Eversense CGM System could give patients yet another tool for managing their health and simplifying their lives,” said Chad Rogers, CEO of TypeZero, in a statement.